Related Experiment Video
Updated: Apr 19, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro
Samantha C Higgins1, Helen L Fillmore2, Keyoumars Ashkan3
1Cellular and Molecular Neuro-oncology Research Group, Cellular and Molecular Medicine Research Division, Institute of Biomedical and Biomolecular Sciences, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, U.K. samantha.higgins@port.ac.uk.
Background:
Effective treatments for glioblastoma multiforme (GBM) are lacking due, in part, to cellular heterogeneity. Consequently, single-target therapeutic strategies are unlikely to succeed. Simultaneous targeting of different neoplastic cell populations within the same tumour may, therefore, prove of value. Neuron-glia 2 (NG2), a transmembrane chondroitin sulphate proteoglycan, present on developing glial cells, and GD3(A), a ganglioside expressed on developing migratory glia, are re-expressed in GBM.
Materials And Methods:
The aims of this study were to conduct 'proof of concept' experiments in human GBM cell lines to show that proliferative high NG2-expressing cells and high GD3(A) -expressing migratory cells could be effectively ablated using a Mab-Zap saporin immunotoxin system.
Results:
The combinatorial ablation of both NG2 and GD3(A)-expressing cells resulted in significant reduction in GBM cell viability compared to single epitope targeting and controls (p<0.0001); non-neoplastic astrocytes were not affected.
Conclusion:
Multiple targeting of GBM sub-populations may, therefore, help inform novel therapeutic approaches.
Insights
Targeting multiple glioblastoma cell types simultaneously, including NG2-expressing and GD3(A)-expressing cells, significantly reduces tumor viability. This combinatorial approach offers a promising strategy for novel glioblastoma multiforme therapies.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Immunotherapy
Background:
- Glioblastoma multiforme (GBM) treatment is challenging due to cellular heterogeneity, limiting single-target therapies.
- Neuron-glia 2 (NG2) and GD3(A) ganglioside are re-expressed in GBM, marking distinct neoplastic cell populations.
Purpose of the Study:
- To demonstrate proof of concept for ablating GBM cells using a Mab-Zap saporin immunotoxin system.
- To evaluate the efficacy of simultaneously targeting NG2-expressing and GD3(A)-expressing GBM cells.
Main Methods:
- Utilized a Mab-Zap saporin immunotoxin system for targeted cell ablation in human GBM cell lines.
- Investigated the combinatorial effect of targeting both NG2 and GD3(A) expressing cells.
Main Results:
- Combinatorial ablation of NG2 and GD3(A) expressing cells significantly reduced GBM cell viability (p<0.0001).
- Single epitope targeting and control groups showed less significant reductions in cell viability.
- Non-neoplastic astrocytes were unaffected by the treatment.
Conclusions:
- Simultaneous targeting of distinct GBM subpopulations is a viable therapeutic strategy.
- This approach may inform the development of novel therapeutic strategies for glioblastoma multiforme.
More Related Videos
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024